Rocket Pharmaceuticals Inc. (RCKT)
Rocket: Danon Disease Treatment Program Should Carry The Tide Until Regulatory Moves
Enrollment completed for pivotal single-arm phase 2 study, using RP-A501 for the treatment of male patients with Danon disease. Promise for RP-A501 program lies with the potential to receive FDA Accelerated Approval for the treatment of male patients with Danon disease. The Danon disease treatment market is expected to reach $2.82 billion by 2030.
RCKT Completes Enrollment in Rare Heart Disease Study, Stock Rises
Rocket completes enrollment of patients in a pivotal phase II study evaluating RP-A501 for treating male patients with Danon disease.
Rocket Stock Down More Than 30% in Past Six Months: Here's Why
The recent regulatory setbacks related to RCKT's pipeline candidate, Kresladi (marnetegragene autotemcel) weigh heavily on the stock.
FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease
Per the FDA, Rocket (RCKT) needs to submit additional manufacturing information on Kresladi gene therapy to secure approval for severe leukocyte adhesion deficiency-I (LAD-I), a rare genetic disorder.
FDA Again Delays Approval of Rocket Pharmaceuticals' Gene Therapy Treatment
Rocket Pharmaceuticals (RCKT) shares declined in intraday trading Friday after the biopharmaceutical firm announced that the Food and Drug Administration (FDA) wants more data about its gene therapy to treat a rare immune disorder in children before granting approval.
Why Is Rocket Pharmaceuticals (RCKT) Down 4.8% Since Last Earnings Report?
Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock?
